Treatment of large cell lymphoma with the Fi2 regimen (doxorubicin, vincristine, cyclophosphamide, bleomycin and prednisone): 25-year experience

Oncology Reports

Volumn 7, Issue 4, 2000, Pages 891-896

  Bellesi, G ^a   Rigacci, L ^a   Longo, G ^a   Alterini, R ^a   Bernardi, F ^a   Messori, A ^a   Trippoli, S ^a   Vaiani, M ^a   Carrai, V ^a   Ferrini, P Rossi ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bleomycin; Cyclophosphamide; Doxorubicin; Large cell lymphoma; Prednisone; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHOP B PROTOCOL; CHOP-B PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTIOCYTIC LYMPHOMA; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 0034222923     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.4.891     Document Type: Article

References (26)

1. Armitase JO: Treatment of non-Hodekin's lymphoma. N Engl J Med 328: 1023-1030, 1993.
2. Armitage JO and Cheson BD: Interpretation of clinical trials in diffuse large cell lymphoma. J Clin Oncol 6: 1335-1347, 1988.
3. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484-1493, 1976.
4. Canellos GP: CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large cell lymphoma. J Clin Oncol 15: 1713-1716, 1997.
5. Sweet DL, Golomb HM, Ultmann JE, et al: Cyclophsphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Int Med 91: 785-790, 1980.
6. Schein PS, De Vita Jr, Hubbard S, et al: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in treatment of advanced diffuse histiocytic lymphoma. Ann Int Med 85: 417-422, 1976.
7. Skarin AJ, Rosenthal DS, Maloney WC and Frei E: Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). Blood 49: 759-770, 1977.
8. Klimo P and Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med 102: 596-602, 1985.
9. Fisher RI, Longo DL, De Vita VT Jr, Hubbard SM, Miller TP and Young RC: Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Ann Oncol 2 (Suppl 1): 33-35, 1991.
10. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
11. Shipp M, Harrington D, Anderson J, et al: International non-Hodskin's lymphoma prognostic factors project. N Engl J Med 329: 987-994, 1993.
12. Hryniuk W and Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288, 1984.
13. Armitage JO, Dick FR, Corder MP, et al: Predicting therapeutic outcome in patients with diffuse histiocyte lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 50: 1695-1702, 1982.
14. Coltmann CA, Dahlberg S, Jones SE, et al: CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up. In: Advances in Cancer Chemotharapy. Skarin AT (ed). Park Row, New York, pp71-77, 1986.
15. Sarles G, Shipp MA and Coiffer B: Chemotherapy of non-Hodgkin's aggressive lymphoma. Semin Hematol 31: 46-69, 1994.
16. Schein PS, De Vita Jr, Hubbard S, et al: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy, in treatment of advanced diffuse histiocytic lymphoma. Ann Int Med 85: 417-422, 1976.
17. Rodriguez V, Cabanillas F, Burgess MA, et al: Combination chemotherapy (CHOP-Bleo) in advanced (non-Hodgkin's) malignant lymphoma. Blood 49: 325-333, 1977.
18. Jones SE, Grozea PN, Metz EN, et al: Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 43: 417-425, 1977.
19. Gaynor ER, Ultmann JE, Colomb HM and Sweet DL: Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol 3: 1596-1604, 1985.
20. Laurence J, Coleman M, Allen SL, Silver RT and Pasmantier M: Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Int Med 97: 190-195, 1982.
21. Fisher RI, De Vita VT Jr, Hubbard SM, et al: Diffuse aggressive lymphomas: increase survival after flexible sequences of ProMACE and MOPP chemotherapy. Ann Int Med 98: 304-309, 1983.
22. Sweetenham JW, Mead GM and Whitehouse JM: Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma. J Clin Oncol 9: 2202-2209, 1991.
23. Lee AY, Connors JM, Klimo P, O'Reilly SE and Gascoyne RD: Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 15: 1745-1753, 1997.
24. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodekin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
25. Linch DC, Hudson BV, Hancock BW, et al: A randomized comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Br J Cancer 74: 318-322, 1996.
26. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327: 1342-1349, 1992.